Header Logo

Connection

LUHUA WANG to Male

Back to Details
This is a "connection" page, showing publications LUHUA WANG has written about Male.
LUHUA WANG
Connection Strength
0.502
Male
  1. Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2. J Immunother Cancer. 2020 10; 8(2).
    View in: PubMed
    Score: 0.022
  2. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. Leukemia. 2019 11; 33(11):2762-2766.
    View in: PubMed
    Score: 0.021
  3. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018 02 17; 391(10121):659-667.
    View in: PubMed
    Score: 0.018
  4. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017 11 02; 10(1):171.
    View in: PubMed
    Score: 0.018
  5. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016 Jan; 17(1):48-56.
    View in: PubMed
    Score: 0.016
  6. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood. 2015 Aug 06; 126(6):739-45.
    View in: PubMed
    Score: 0.015
  7. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015 Jun; 26(6):1175-1179.
    View in: PubMed
    Score: 0.015
  8. Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study. J Hematol Oncol. 2014 May 09; 7:41.
    View in: PubMed
    Score: 0.014
  9. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol. 2014 May; 165(4):510-8.
    View in: PubMed
    Score: 0.014
  10. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Blood. 2013 Oct 31; 122(18):3122-8.
    View in: PubMed
    Score: 0.014
  11. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. Mol Cancer Ther. 2013 Nov; 12(11):2494-504.
    View in: PubMed
    Score: 0.014
  12. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013 Aug 08; 369(6):507-16.
    View in: PubMed
    Score: 0.013
  13. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013 Sep; 27(9):1902-9.
    View in: PubMed
    Score: 0.013
  14. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. Clin Cancer Res. 2013 Apr 15; 19(8):2248-56.
    View in: PubMed
    Score: 0.013
  15. High frequencies of response after limited primary therapy for multiple myeloma. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):119-22.
    View in: PubMed
    Score: 0.013
  16. Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma. Am J Clin Oncol. 2012 Dec; 35(6):562-5.
    View in: PubMed
    Score: 0.013
  17. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012 Sep; 158(6):739-48.
    View in: PubMed
    Score: 0.013
  18. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012 Jul; 13(7):716-23.
    View in: PubMed
    Score: 0.012
  19. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer. 2012 Aug 01; 118(15):3793-800.
    View in: PubMed
    Score: 0.012
  20. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo. Leuk Res. 2012 Mar; 36(3):363-8.
    View in: PubMed
    Score: 0.012
  21. Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res. 2011 Mar; 35(3):380-6.
    View in: PubMed
    Score: 0.011
  22. Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD). Hematology. 2010 Apr; 15(2):70-3.
    View in: PubMed
    Score: 0.011
  23. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009 Nov 01; 27(31):5213-8.
    View in: PubMed
    Score: 0.010
  24. Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma. Cancer. 2008 Dec 01; 113(11):3231-41.
    View in: PubMed
    Score: 0.010
  25. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer. 2008 Nov 15; 113(10):2734-41.
    View in: PubMed
    Score: 0.010
  26. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008 Aug 15; 113(4):791-8.
    View in: PubMed
    Score: 0.010
  27. A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res. 2008 Apr 01; 14(7):2154-60.
    View in: PubMed
    Score: 0.009
  28. Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2008 Jan; 22(1):179-85.
    View in: PubMed
    Score: 0.009
  29. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer. 2006 Nov; 42(17):2976-81.
    View in: PubMed
    Score: 0.008
  30. Testicular lymphoma: a mysterious link between the testis and the brain. Clin Lymphoma. 2002 Dec; 3(3):173-4.
    View in: PubMed
    Score: 0.006
  31. High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. Bone Marrow Transplant. 2015 May; 50(5):668-72.
    View in: PubMed
    Score: 0.004
  32. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett. 2015 Feb 01; 357(1):179-185.
    View in: PubMed
    Score: 0.004
  33. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov; 15(12):1311-8.
    View in: PubMed
    Score: 0.004
  34. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):152-8.
    View in: PubMed
    Score: 0.004
  35. Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients. Clin Lymphoma Myeloma Leuk. 2014 Dec; 14(6):474-9.
    View in: PubMed
    Score: 0.004
  36. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer. 2014 Jul 29; 111(3):628-36.
    View in: PubMed
    Score: 0.004
  37. Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. Bone Marrow Transplant. 2014 Aug; 49(8):1036-41.
    View in: PubMed
    Score: 0.004
  38. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol. 2013 Dec 10; 6:92.
    View in: PubMed
    Score: 0.003
  39. Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma. Br J Haematol. 2013 Dec; 163(5):611-20.
    View in: PubMed
    Score: 0.003
  40. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013 Dec; 27(12):2351-6.
    View in: PubMed
    Score: 0.003
  41. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 2012 Nov 01; 120(18):3783-92.
    View in: PubMed
    Score: 0.003
  42. Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study. Hum Pathol. 2013 Jan; 44(1):110-21.
    View in: PubMed
    Score: 0.003
  43. Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production. Br J Haematol. 2012 Oct; 159(2):243-6.
    View in: PubMed
    Score: 0.003
  44. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Oct 04; 120(14):2817-25.
    View in: PubMed
    Score: 0.003
  45. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012 Jun 14; 119(24):5661-70.
    View in: PubMed
    Score: 0.003
  46. Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol. 2012 Mar; 87(3):272-6.
    View in: PubMed
    Score: 0.003
  47. Mantle cell lymphoma as a component of composite lymphoma: clinicopathologic parameters and biologic implications. Hum Pathol. 2012 Apr; 43(4):467-80.
    View in: PubMed
    Score: 0.003
  48. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012 Jun; 23(6):1640-5.
    View in: PubMed
    Score: 0.003
  49. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer. 2012 May 01; 118(9):2507-15.
    View in: PubMed
    Score: 0.003
  50. Feasibility of autologous hematopoietic stem cell transplant in patients aged =70 years with multiple myeloma. Leuk Lymphoma. 2012 Jan; 53(1):118-22.
    View in: PubMed
    Score: 0.003
  51. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol. 2011 Jun; 86(6):484-7.
    View in: PubMed
    Score: 0.003
  52. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Haematol. 2010 Oct; 151(1):47-53.
    View in: PubMed
    Score: 0.003
  53. Outcomes in lymphoma patients with obstructive jaundice: a cancer center experience. Dig Dis Sci. 2010 Nov; 55(11):3271-7.
    View in: PubMed
    Score: 0.003
  54. Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma. Bone Marrow Transplant. 2011 Apr; 46(4):510-5.
    View in: PubMed
    Score: 0.003
  55. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica. 2010 Oct; 95(10):1738-44.
    View in: PubMed
    Score: 0.003
  56. Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1122-9.
    View in: PubMed
    Score: 0.003
  57. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood. 2009 Oct 01; 114(14):3074-83.
    View in: PubMed
    Score: 0.003
  58. Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jul; 15(7):812-6.
    View in: PubMed
    Score: 0.003
  59. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jun; 15(6):718-23.
    View in: PubMed
    Score: 0.003
  60. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant. 2008 Dec; 14(12):1401-7.
    View in: PubMed
    Score: 0.002
  61. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22; 357(21):2133-42.
    View in: PubMed
    Score: 0.002
  62. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant. 2007 Sep; 13(9):1066-72.
    View in: PubMed
    Score: 0.002
  63. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2007 Aug; 138(4):502-5.
    View in: PubMed
    Score: 0.002
  64. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant. 2007 Mar; 39(5):279-83.
    View in: PubMed
    Score: 0.002
  65. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma. J Infect Dis. 2006 Nov 15; 194(10):1394-7.
    View in: PubMed
    Score: 0.002
  66. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005 Oct 01; 23(28):7013-23.
    View in: PubMed
    Score: 0.002
  67. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005 Feb 01; 23(4):667-75.
    View in: PubMed
    Score: 0.002
  68. Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma. J Clin Oncol. 2004 Oct 15; 22(20):4095-102.
    View in: PubMed
    Score: 0.002
  69. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Semin Hematol. 2003 Oct; 40(4 Suppl 4):3-7.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.